公开(公告)号：US20230002507A1

公开(公告)日：2023-01-05

申请号：US17670270

申请日：2022-02-11

Applicant: Novartis AG

Inventor： Carola FRIEDMAN ,  Yasser KHDER ,  Martin LEFKOWITZ

IPC: C07K16/36 ,  A61P7/02 ,  A61K9/00

Abstract: The present invention relates to methods of preventing, treating or managing, reducing the risk of stroke or thromboembolism in a subject afflicted with end stage renal disease comprising administering a pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof that bind to human Factor XI and/or activated Factor XI (“Factor XIa”).

公开(公告)号：US20210077461A1

公开(公告)日：2021-03-18

申请号：US17103327

申请日：2020-11-24

Applicant: Novartis AG

Inventor： Victor Chengwei SHI ,  Martin LEFKOWITZ ,  Adel Remond RIZKALA

IPC: A61K31/41 ,  A61K45/06 ,  A61K31/225 ,  A61K31/401 ,  A61K9/00 ,  A61K31/216

Abstract: The present invention relates to methods and pharmaceutical compositions for the prevention or in delaying time to first occurrence of mortality, in particular cardiovascular death, and/or of cardiovascular hospitalizations in a patient suffering from chronic systolic heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said patient.

公开(公告)号：US20200231701A1

公开(公告)日：2020-07-23

申请号：US16472641

申请日：2017-12-22

Applicant: Novartis AG

Inventor： Carola FRIEDMAN ,  Yasser KHDER ,  Martin LEFKOWITZ

IPC: C07K16/36 ,  A61P7/02 ,  A61K9/00

Abstract: The present invention relates to methods of preventing, treating or managing, reducing the risk of stroke or thromboembolism in a subject afflicted with end stage renal disease comprising administering a pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof that bind to human Factor XI and/or activated Factor XI (“Factor XIa”).